60 related articles for article (PubMed ID: 11501176)
41. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.
Zisaki A; Miskovic L; Hatzimanikatis V
Curr Pharm Des; 2015; 21(6):806-22. PubMed ID: 25341854
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
Zhou YT; Yu LS; Zeng S; Huang YW; Xu HM; Zhou Q
Ther Clin Risk Manag; 2014; 10():17-26. PubMed ID: 24379677
[TBL] [Abstract][Full Text] [Related]
43. Effect of natural borneol on the pharmacokinetics and distribution of nimodipine in mice.
Wu C; Liao Q; Yao M; Xu X; Zhou Y; Hou X; Xie Z
Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):17-24. PubMed ID: 23673491
[TBL] [Abstract][Full Text] [Related]
44. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort.
Zhao Y; Zhai D; He H; Li T; Chen X; Ji H
Eur J Clin Pharmacol; 2009 Jun; 65(6):579-84. PubMed ID: 19205682
[TBL] [Abstract][Full Text] [Related]
45. Chiral metabolism of propafenone in rat hepatic microsomes treated with two inducers.
Zhou Q; Yao TW; Zeng S
World J Gastroenterol; 2001 Dec; 7(6):830-5. PubMed ID: 11854911
[TBL] [Abstract][Full Text] [Related]
46. Metabolism and metabolic inhibition of cilnidipine in human liver microsomes.
Liu XQ; Zhao Y; Li D; Qian ZY; Wang GJ
Acta Pharmacol Sin; 2003 Mar; 24(3):263-8. PubMed ID: 12617777
[TBL] [Abstract][Full Text] [Related]
47. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes.
Zhao XP; Zhong J; Liu XQ; Wang GJ
Acta Pharmacol Sin; 2007 Jan; 28(1):118-24. PubMed ID: 17184591
[TBL] [Abstract][Full Text] [Related]
48. [Metabolic kinetics of MN9202 in Beagle dog liver microsomes].
Yang ZF; Zhou SY; Mei QB; Yang TH; Liu ZG
Yao Xue Xue Bao; 2005 Nov; 40(11):1019-23. PubMed ID: 16499087
[TBL] [Abstract][Full Text] [Related]
49. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation.
Obach RS
Drug Metab Dispos; 2000 Sep; 28(9):1069-76. PubMed ID: 10950851
[TBL] [Abstract][Full Text] [Related]
50. Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.
Perloff MD; Von Moltke LL; Greenblatt DJ
Xenobiotica; 2003 Apr; 33(4):365-77. PubMed ID: 12745872
[TBL] [Abstract][Full Text] [Related]
51. Drug metabolism in liver disease.
Howden CW; Birnie GG; Brodie MJ
Pharmacol Ther; 1989; 40(3):439-74. PubMed ID: 2646653
[No Abstract] [Full Text] [Related]
52. Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes.
Liu XQ; Ren YL; Qian ZY; Wang GJ
Acta Pharmacol Sin; 2000 Aug; 21(8):690-4. PubMed ID: 11501176
[TBL] [Abstract][Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
